yfimuna.wordpress.com
Hematide is in a Phase III Renton led Onyx for nearly 15 stepping down in February 2008as president, CEO, chairman and a membee of Onyx’s board. At the company, he helped negotiatse a research, development and commercialization partnership with that resultexd inthe anti-cancer drug Nexavar. Nexavar tablets, which cost about $5,0009 a month in the United States and areapproaching $1 billion in annual sales, are approvedd in more than 80 countrieds to treat kidney cancer and 70-plus countriex for liver cancer. Prior to joining Onyx, Renton was presidenft and COOof Chiron, which acquired Cetus in 1991.
Renton had been presidentr of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987. Renton also serves on the boardsof , Cepheis and the Special Olympics of Northern
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment